Safety and Feasibility Evaluation of Automated User Profile Settings Initialization and Adaptation With Control-IQ...

Area of Science:

• Endocrinology
• Diabetes Technology
• Metabolic Disorders

Background:

• Automated insulin delivery (AID) systems require precise setting optimization for effective glycemic control in type 1 diabetes (T1D).
• The t:slim X2 insulin pump with Control-IQ technology offers advanced features for diabetes management.
• Evaluating automated systems for setting initialization and adjustment is crucial for clinical adoption.

Purpose of the Study:

• To assess the safety and efficacy of a computerized system for initializing and adjusting Control-IQ technology settings in adults with T1D.
• To determine if automated setting optimization improves glycemic outcomes compared to baseline therapy.

Main Methods:

• Adults with T1D on multiple daily injections (MDI) underwent a 2-week continuous glucose monitoring (CGM) run-in.
• Participants were transitioned to the t:slim X2 insulin pump with Control-IQ technology for 13 weeks.
• A computerized algorithm provided automated recommendations for initial and weekly adjustments of pump settings (basal rate, insulin-to-carbohydrate ratio, correction factor), with physician override available.

Main Results:

• Time in range (70-180 mg/dL) significantly improved from 45.7% to 69.1% (median increase of 18.8%, P < .001), sustained over 13 weeks.
• The percentage of participants achieving HbA1c <7% increased from 0% to 55% (P < .001).
• Automated setting adaptations were rarely overridden (1.9%), indicating system reliability and safety.

Conclusions:

• Computerized initiation and adaptation of Control-IQ settings are safe for adults with T1D transitioning from MDI.
• This simplified system can enhance AID adoption and reduce clinical workload.
• Automated optimization of AID settings offers a promising approach to improve glycemic management in T1D.